By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Lixte Biotechnology 



East Setauket  New York    U.S.A.
Phone: Fax:


SEARCH JOBS


Industry
Biotechnology






Company News
Lixte Biotechnology's Lead Compound Lb-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer 6/18/2014 10:47:05 AM
Lixte Biotechnology's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer 6/18/2014 10:33:46 AM
Dr. Daniel Von Hoff Joins Lixte Biotechnology's Scientific Advisory Board 1/7/2014 8:04:55 AM
Lixte Biotechnology Announces Initiation of a Phase I Trial of Its Lead Anti-Cancer Compound, LB-100 4/25/2013 11:30:35 AM
Lixte Biotechnology Holdings Announces New Appointment to Board of Directors 11/27/2012 9:07:08 AM
Lixte Biotechnology Announces Increased Funding and FDA Allowance to Conduct A Phase I Trial of Its Lead Anti-Cancer Compound, LB-100 7/31/2012 12:30:00 PM
Lixte Biotechnology Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a First-in-Class, Anti-Cancer Compound 5/1/2012 12:44:28 PM
Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor 4/4/2012 9:58:21 AM
Lixte Biotechnology Announces Issuance of U.S. Patent for Agents for the Treatment of Neurodegenerative Diseases 1/9/2012 12:05:24 PM
Lixte Biotechnology Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 12/19/2011 10:41:34 AM
123
//-->